Mark Sculpher mostly deals with Health care, Randomized controlled trial, Economic evaluation, Cost-effectiveness analysis and Health technology. His study connects Management science and Health care. His Randomized controlled trial research is multidisciplinary, incorporating perspectives in Placebo, Physical therapy, Arthroplasty and Hazard ratio.
His Economic evaluation research integrates issues from Psychological intervention, Key and Engineering ethics. His research in Cost-effectiveness analysis intersects with topics in Actuarial science and Econometrics. His Surgery study combines topics from a wide range of disciplines, such as Internal medicine and Clinical trial.
His main research concerns Economic evaluation, Health care, Randomized controlled trial, Quality-adjusted life year and Cost-effectiveness analysis. The various areas that he examines in his Economic evaluation study include Health technology, Management science and Health economics. His Health care research incorporates elements of Psychological intervention, Public economics, Actuarial science, Risk analysis and Opportunity cost.
The study incorporates disciplines such as Physical therapy, Quality of life and Clinical trial in addition to Randomized controlled trial. His work carried out in the field of Quality-adjusted life year brings together such families of science as Surgery and Intensive care medicine. His research in Internal medicine is mostly focused on Myocardial infarction.
The scientist’s investigation covers issues in Economic evaluation, Health care, Psychological intervention, Public economics and Health economics. He performs multidisciplinary study in Economic evaluation and Context in his work. The concepts of his Health care study are interwoven with issues in Opportunity cost, Personalized medicine and Management science.
His Management science research includes elements of Conceptual framework and Critical appraisal. The Psychological intervention study combines topics in areas such as Actuarial science, Risk analysis, Investment and Intensive care medicine. The Decision model study which covers Expected value of perfect information that intersects with Quality-adjusted life year.
Mark Sculpher spends much of his time researching Health care, Psychological intervention, Economic evaluation, Value and Cost-effectiveness analysis. His Health care study incorporates themes from Multiple-criteria decision analysis, Management science and Decision analysis. Mark Sculpher works mostly in the field of Psychological intervention, limiting it down to concerns involving Actuarial science and, occasionally, Emerging technologies, Set and Dynamic pricing.
His work often combines Economic evaluation and Context studies. His Value study integrates concerns from other disciplines, such as Cost–utility analysis, Risk analysis and Investment. His studies in Cost-effectiveness analysis integrate themes in fields like Manual therapy, Quality of life, Meta-analysis, Selection bias and Prostate cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Methods for the Economic Evaluation of Health Care Programmes
Michael F. Drummond;Mark J. Sculpher;Karl Claxton;Greg L. Stoddart.
Decision Modelling for Health Economic Evaluation
Andrew Briggs;Karl Claxton;Mark J Sculpher.
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders;Peter J. Neumann;Anirban Basu;Dan W. Brock.
Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses.
R Fitzpatrick;E Shortall;M Sculpher;D Murray.
Health Technology Assessment (1998)
Representing uncertainty: the role of cost-effectiveness acceptability curves.
Elisabeth Fenwick;Karl Claxton;Mark Sculpher.
AN INTRODUCTION TO MARKOV MODELLING FOR ECONOMIC EVALUATION
Andrew Briggs;Mark Sculpher.
Estimating mean QALYs in trial-based cost-effectiveness analysis : the importance of controlling for baseline utility
Andrea Manca;Neil Hawkins;Mark J. Sculpher.
Health Economics (2005)
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
Karl Philip Claxton;Stephen Martin;Marta O Soares;Nigel Rice.
Health Technology Assessment (2015)
Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial
R.M. Greenhalgh;L.C. Brown;D. Epstein;G.P.S. Kwong.
Review of guidelines for good practice in decision-analytic modelling in health technology assessment
Z Philips;L Ginnelly;M Sculpher;K Claxton.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: